Health · 1 sources covering this

STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early

In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/7f18e5beb8ac1b183c4d1f3a9d7ae878a05e4894"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early"></iframe>

STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early

How 1 sources are covering this

STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early

More from Health

STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclear

STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial

STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

Reader

Trust & legal

Across the network